Your AI-Trained Oncology Knowledge Connection!

Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management : Episode 23

Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer

May 25, 2022

By David Aggen, MD, PhD
Robert S. Alter, MD

Video

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

EP: 1.Trends in RCC Incidence

EP: 2.RCC Histologies

EP: 3.Risk Models and Prognostic Factors

EP: 4.Metastatic RCC: Prognosis and Recent Advances in Care

EP: 5.Biomarker Testing in RCC: Current Approaches

EP: 6.Biomarker Testing: Methodologies, Sample Types, and Emerging Data

EP: 7.Prognostic Value of Biomarkers in RCC

EP: 8.The Role of Genetic Mutations in Prognosis and Decision-Making

EP: 9.Comparison of Older First-Line, Single-Agent Therapies

EP: 10.Newer First-Line Combination Therapy Options

EP: 11.Evolution of Combination Therapy As The Standard of Care

EP: 12.Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens

EP: 13.Safety and Efficacy Data: The CheckMate 214 Trial

EP: 14.Safety and Efficacy Data: The JAVELIN Renal 101 Trial

EP: 15.Safety and Efficacy Data: The KEYNOTE-426 Trial

EP: 16.Safety and Efficacy Data: The CheckMate 9ER Trial

EP: 17.Safety and Efficacy Data: The CLEAR Trial

EP: 18.Common Adverse Events with Single-Agent or Combination Therapy

EP: 19.Balancing Treatment Efficacy with Toxicity in Metastatic RCC

EP: 20.Strategies for Prevention and Management of Adverse Events

EP: 21.Patient-Specific Factors Impacting Treatment Choices in RCC

EP: 22.Considerations for Patient-Focused, Shared Decision-Making in RCC

EP: 23.Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer

EP: 24.The Importance of Team-Based Management and Patient Communication

EP: 25.OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC

EP: 26.Reflections on Novel Targets and Emerging Regimens for RCC

EP: 27.Clinical Pearls on Recent Advances and the Future of Treatment in RCC

EP: 28.Recap: Safety and Efficacy of Available Treatment Options and Considerations for Management of RCC

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.

Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.